These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39412628)

  • 1. A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty.
    Yu X; Cheng X; Wei H; Xu X; Gong C; Li G; Yao H; Zhou L; Zhong Y; Yang Y; Luo F; Zhang Y; Huang F; Shi X; Cabri P; Luo X
    Adv Ther; 2024 Dec; 41(12):4537-4556. PubMed ID: 39412628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study.
    Luo X; Zhang C; Yang Y; Xu X; Cheng X; Wei H; Wang L; Huang F; Shi X; Cabri P
    Adv Ther; 2023 Oct; 40(10):4574-4588. PubMed ID: 37584898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.
    Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
    J Korean Med Sci; 2021 Aug; 36(34):e219. PubMed ID: 34463062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K; Yang J; Aisenberg J; Wright N; Kaplowitz P; Lahlou N; Linares J; Lundström E; Purcea D; Cassorla F
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1241-1248. PubMed ID: 26887034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
    Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
    Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty.
    Yoo E; Kim S; Jung HL; Shim JY; Shim JW; Kim DS; Kwak JH; Kim ES; Yang A
    Front Endocrinol (Lausanne); 2023; 14():1134977. PubMed ID: 36875449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
    Zenaty D; Blumberg J; Liyanage N; Jacqz-Aigrain E; Lahlou N; Carel JC;
    Horm Res Paediatr; 2016; 86(3):188-195. PubMed ID: 27603324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.
    Martínez-Aguayo A; Hernández MI; Beas F; Iñiguez G; Avila A; Sovino H; Bravo E; Cassorla F
    J Pediatr Endocrinol Metab; 2006 Aug; 19(8):963-70. PubMed ID: 16995580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
    Liang Y; Wei H; Zhang JL; Hou L; Luo XP
    Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation
.
    Durand A; Tauber M; Patel B; Dutailly P
    Horm Res Paediatr; 2017; 87(4):224-232. PubMed ID: 28334719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of subcutaneous administration of gonadotropin-releasing hormone agonist on idiopathic central precocious puberty.
    Liang Y; Wei H; Zhang J; Hou L; Luo X
    J Huazhong Univ Sci Technolog Med Sci; 2006; 26(5):558-61. PubMed ID: 17219967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
    J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptorelin stimulated luteinizing hormone concentrations for diagnosing central precocious puberty: study of diagnostic accuracy.
    Vukovic R; Milenkovic T; Soldatovic I; Pekic S; Mitrovic K; Todorovic S
    Endocrine; 2022 Mar; 75(3):934-941. PubMed ID: 34826116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist.
    Oostdijk W; Hümmelink R; Odink RJ; Partsch CJ; Drop SL; Lorenzen F; Sippell WG; van der Velde EA; Schultheiss H
    Eur J Pediatr; 1990 Feb; 149(5):308-13. PubMed ID: 2138079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Levels of Thyroid Stimulating Hormone and Luteinizing Hormone Are Decreased in Girls with Central Precocious Puberty after 12-Month GnRH Agonist Treatment.
    Kim YJ; Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
    Tohoku J Exp Med; 2020 Nov; 252(3):193-197. PubMed ID: 33087637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
    Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A
    Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central precocious puberty in girls: Diagnostic study and auxological response to triptorelin treatment.
    Durá-Travé T; Ortega Pérez M; Ahmed-Mohamed L; Moreno-González P; Chueca Guindulain MJ; Berrade-Zubiri S
    Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(7):410-416. PubMed ID: 30808564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central precocious puberty: treatment with triptorelin 11.25 mg.
    Chiocca E; Dati E; Baroncelli GI; Cassio A; Wasniewska M; Galluzzi F; Einaudi S; Cappa M; Russo G; Bertelloni S
    ScientificWorldJournal; 2012; 2012():583751. PubMed ID: 22645436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.